2 weeks Ago By Defense World Staff
Rhumbline Advisers grew its holdings in shares of Invivyd, Inc. ( NASDAQ:IVVD – Free Report ) by 4,434.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The firm owned 84,017 shares of the company’s stock after buying an additional 82,164 shares during the quarter. Rhumbline Advisers owned 0.07% of Invivyd worth $92,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in IVVD. SG Americas Securities LLC purchased a new position in Invivyd in the first quarter valued at about $56,000. Tidal Investments LLC bought a new position in Invivyd during the first quarter worth $126,000.
Chase Investment Counsel Corp bought a new position in Invivyd during the first quarter worth $271,000. Acadian Asset Management LLC acquired a new position in Invivyd in the first quarter worth $905,000. Finally, Bank of New York Mellon Corp bought a new stake in Invivyd during the second quarter valued at $263,000.
Institutional investors and hedge funds own 70.36% of the company’s stock. Invivyd Stock Performance Shares of IVVD stock opened at $1.
02 on Tuesday. The firm has a market capitalization of $121.70 million, a PE ratio of -0.
55 and a beta of 0.61. The stock has a fifty day moving average of $1.
05 and a two-hundred day moving average of $1.79. Invivyd, Inc.
has a 1 year low of $0.81 and a 1 year high of $5.20.
Analyst Upgrades and Downgrades Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Invivyd in a research report on Tuesday, September 3rd. Get Our Latest Stock Report on Invivyd Invivyd Profile ( Free Report ) Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Further Reading Five stocks we like better than Invivyd How to Use the MarketBeat Dividend Calculator TJX Stock: A Buying Opportunity Before the Holiday Rush How to Use the MarketBeat Stock Screener Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge Which Wall Street Analysts are the Most Accurate? Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Want to see what other hedge funds are holding IVVD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivyd, Inc.
( NASDAQ:IVVD – Free Report ). Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter .
.
